Controlled dangerous substances; adding chemicals to Schedule I; effective date.
HB1311 amends Oklahoma’s Uniform Controlled Dangerous Substances Act by expanding Schedule I to include a large number of additional chemicals and chemical families. The bill adds specific opioids and opium derivatives, numerous synthetic cannabinoids, and a broad set of hallucinogens, stimulants, depressants, and emerging designer drugs, including fentanyl analogs, nitazenes, cathinones, tryptamines, and related compounds. It also includes structural class definitions intended to capture future variants of synthetic cannabinoids and related substances, not just the named compounds.
The bill further addresses industrial chemicals that can be misused as intoxicants, such as gamma-butyrolactone (GBL), gamma hydroxyvalerate (GHV), gamma valerolactone (GVL), and 1,4-butanediol, while preserving exclusions for legitimate industrial uses and allowing the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control to exempt qualifying products after notice and hearing. It also provides that federally approved prescription drugs that are rescheduled or deleted under federal law will be treated consistently under state law unless the Oklahoma State Board of Pharmacy acts otherwise. The act is set to take effect November 1, 2025.
HB1311 would broaden the list of substances treated as Schedule I controlled dangerous substances in Oklahoma, increasing criminal and regulatory exposure for possession, manufacture, distribution, and related conduct involving the newly listed compounds. It would also give state law a more flexible framework for addressing new synthetic drugs by using chemical-class definitions and by aligning certain state scheduling decisions with federal DEA actions. The bill affects the Uniform Controlled Dangerous Substances Act, the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control, and the State Board of Pharmacy, while preserving limited exemptions for legitimate industrial and food-related uses of certain chemicals.
No committee transcript or recorded vote information is provided, so there is no direct evidence of debate or opposition in the available materials. Based on the bill text alone, the measure appears to be a public-safety and drug-control bill aimed at keeping pace with evolving synthetic drugs and fentanyl-related substances. The overall posture is precautionary and enforcement-oriented rather than permissive.
The main likely point of contention is the breadth of the scheduling language, especially the inclusion of large chemical families and “modified by replacement” provisions that can reach future analogs not specifically named. Critics of such bills often argue that broad class-based scheduling can sweep in legitimate research, industrial, or pharmaceutical compounds, while supporters typically view that breadth as necessary to prevent rapid circumvention by illicit manufacturers. Another possible issue is the treatment of industrial chemicals like GBL and 1,4-butanediol, where the bill tries to balance abuse prevention with exemptions for legitimate commercial uses.